Newborn Screening for Cystic Fibrosis
The introduction and widespread implementation of newborn bloodspot screening (NBS) for cystic fibrosis (CF) has offered earlier diagnosis and better outcomes for children with CF in many countries of the world. It represents a paradigm shift in the diagnostic pathway for these families. In contrast...
Saved in:
HerausgeberIn: | |
---|---|
Sonstige: | |
Year of Publication: | 2020 |
Language: | English |
Physical Description: | 1 electronic resource (126 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993545618104498 |
---|---|
ctrlnum |
(CKB)5400000000041122 (oapen)https://directory.doabooks.org/handle/20.500.12854/69072 (EXLCZ)995400000000041122 |
collection |
bib_alma |
record_format |
marc |
spelling |
Barben, Jürg edt Newborn Screening for Cystic Fibrosis Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020 1 electronic resource (126 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier The introduction and widespread implementation of newborn bloodspot screening (NBS) for cystic fibrosis (CF) has offered earlier diagnosis and better outcomes for children with CF in many countries of the world. It represents a paradigm shift in the diagnostic pathway for these families. In contrast to a clinical diagnosis, infants are now referred for diagnostic testing after a positive NBS result. The introduction of NBS has enabled the provision of early appropriate treatment to prevent the manifestations of the disease. In the near future, early diagnosis will facilitate the prompt use of new CFTR modulator therapies that correct the basic underlying molecular defect. NBS for CF has been a global success but continues to raise questions with many varied approaches and the development of new technologies, in particular the ability to undertake extensive gene examination. Which is the best protocol to achieve high sensitivity and specificity, and how to evaluate and manage infants with inconclusive diagnosis are all subjects of ongoing discussion. It is also open to question: what is the best approach to informing and counselling the parents about a positive or inconclusive NBS result? These questions are not easy to answer and require a balanced solution that reflects the local health care system and may appropriately result in different answers around the globe. The articles in this book try to answer these questions and give an overview of the current state of knowledge in NBS for CF. English Medicine bicssc newborn screening immunoreactive trypsin(ogen) dried blood spot radioimmunoassay DNA cystic fibrosis incidence malnutrition cost health policy CF transmembrane conductance regulator-related metabolic syndrome CF screen positive inconclusive diagnosis DNA analysis next generation sequencing extended genetic analysis presumptive diagnosis sweat test parental information newborn bloodspot screening psychological impact biochemical screening pancreatitis associated protein immunoreactive trypsinogen cystic fibrosis screen positive inconclusive diagnosis (CFSPID) bioethics newborn screen target disorder missed case sensitivity CFSPID immunoreactive trypsin meconium ileus diagnosis therapy prognosis 3-03936-990-3 3-03936-991-1 Southern, Kevin edt Barben, Jürg oth Southern, Kevin oth |
language |
English |
format |
eBook |
author2 |
Southern, Kevin Barben, Jürg Southern, Kevin |
author_facet |
Southern, Kevin Barben, Jürg Southern, Kevin |
author2_variant |
j b jb k s ks |
author2_role |
HerausgeberIn Sonstige Sonstige |
title |
Newborn Screening for Cystic Fibrosis |
spellingShingle |
Newborn Screening for Cystic Fibrosis |
title_full |
Newborn Screening for Cystic Fibrosis |
title_fullStr |
Newborn Screening for Cystic Fibrosis |
title_full_unstemmed |
Newborn Screening for Cystic Fibrosis |
title_auth |
Newborn Screening for Cystic Fibrosis |
title_new |
Newborn Screening for Cystic Fibrosis |
title_sort |
newborn screening for cystic fibrosis |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2020 |
physical |
1 electronic resource (126 p.) |
isbn |
3-03936-990-3 3-03936-991-1 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT barbenjurg newbornscreeningforcysticfibrosis AT southernkevin newbornscreeningforcysticfibrosis |
status_str |
n |
ids_txt_mv |
(CKB)5400000000041122 (oapen)https://directory.doabooks.org/handle/20.500.12854/69072 (EXLCZ)995400000000041122 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Newborn Screening for Cystic Fibrosis |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField |
_version_ |
1787548875128569856 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03778nam-a2200757z--4500</leader><controlfield tag="001">993545618104498</controlfield><controlfield tag="005">20231214133546.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202105s2020 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000041122</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/69072</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000041122</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Barben, Jürg</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Newborn Screening for Cystic Fibrosis</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel, Switzerland</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (126 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The introduction and widespread implementation of newborn bloodspot screening (NBS) for cystic fibrosis (CF) has offered earlier diagnosis and better outcomes for children with CF in many countries of the world. It represents a paradigm shift in the diagnostic pathway for these families. In contrast to a clinical diagnosis, infants are now referred for diagnostic testing after a positive NBS result. The introduction of NBS has enabled the provision of early appropriate treatment to prevent the manifestations of the disease. In the near future, early diagnosis will facilitate the prompt use of new CFTR modulator therapies that correct the basic underlying molecular defect. NBS for CF has been a global success but continues to raise questions with many varied approaches and the development of new technologies, in particular the ability to undertake extensive gene examination. Which is the best protocol to achieve high sensitivity and specificity, and how to evaluate and manage infants with inconclusive diagnosis are all subjects of ongoing discussion. It is also open to question: what is the best approach to informing and counselling the parents about a positive or inconclusive NBS result? These questions are not easy to answer and require a balanced solution that reflects the local health care system and may appropriately result in different answers around the globe. The articles in this book try to answer these questions and give an overview of the current state of knowledge in NBS for CF.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">newborn screening</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunoreactive trypsin(ogen)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dried blood spot</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">radioimmunoassay</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cystic fibrosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">incidence</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">malnutrition</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cost</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">health policy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CF transmembrane conductance regulator-related metabolic syndrome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CF screen positive</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inconclusive diagnosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DNA analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">next generation sequencing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">extended genetic analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">presumptive diagnosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sweat test</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">parental information</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">newborn bloodspot screening</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">psychological impact</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biochemical screening</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pancreatitis associated protein</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunoreactive trypsinogen</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cystic fibrosis screen positive</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inconclusive diagnosis (CFSPID)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bioethics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">newborn screen</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">target disorder</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">missed case</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sensitivity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CFSPID</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunoreactive trypsin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">meconium ileus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">diagnosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prognosis</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03936-990-3</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03936-991-1</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Southern, Kevin</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Barben, Jürg</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Southern, Kevin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:57:38 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337998020004498&Force_direct=true</subfield><subfield code="Z">5337998020004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337998020004498</subfield></datafield></record></collection> |